关于睾丸生殖细胞肿瘤中MiR-371a-3p的研究进展  

Research Progress on MiR-371a-3p in Testicular Germ Cell Tumors

作　　者：刘盼 刘志波 

机构地区：[1]青海大学研究生院,青海 西宁 [2]青海红十字医院肿瘤内科,青海 西宁

出　　处：《临床医学进展》2023年第7期11555-11559,共5页Advances in Clinical Medicine

摘　　要：睾丸生殖细胞肿瘤(TGCTs)来源于未分化的胚胎生殖细胞,在模仿胚胎和胚外发育阶段的同时保留胚胎生殖细胞的生物学和生化特征。在TGCTs的临床实践中有3种常用的经典肿瘤标志物,分别为甲胎蛋白、β人绒毛膜促性腺激素和乳酸脱氢酶,虽然这些肿瘤标志物在临床中常用于诊断、风险评估和确定患者病情,但是目前使用的生物标志物敏感性和特异性低于60%,不利于TGCTs的临床治疗。有研究指出循环microRNAs在TGCTs中有特异性,并可能满足临床需求。本文就TGCTs中miR-371a-3p的研究进展作一综述。Testicular germ cell tumors (TGCTs) are derived from undifferentiated embryonic germ cells that mimic embryonic and extraembryonic developmental stages while preserving the biological and biochemical characteristics of embryonic germ cells. In the clinical practice of TGCTs, there are three commonly used classical tumor markers, namely alpha-fetoprotein, β human chorionic gon-adotropin and lactate dehydrogenase, although these tumor markers are commonly used in clinical diagnosis, risk assessment and determination of patients’ conditions, but the sensitivity and speci-ficity of biomarkers currently used are less than 60%, which is not conducive to the clinical treat-ment of TGCTs. Circulating microRNAs have been shown to be specific in TGCTs and may meet clini-cal needs. This article reviews the research progress of miR-371a-3p in TGCTs.

关 键 词：睾丸生殖细胞肿瘤 肿瘤标志物 MiR-371a-3p 

分 类 号：R73[医药卫生—肿瘤]